Beconase - Beclomethasone Dipropionate Aqueous Nasal Spray
Online Beconase from Kiwi Drug New Zealand Pharmacy
Only $10.73 USD (200 Sprays) - Buy Beconase
Theres nothing worse than sinus pain, nasal congestion and hay fever. Allergies, when bad, can be somewhat debilitating. Sufferers from certain allergies can not enjoy a full life as they have to continuously be on their guard to try and evade the onset of an allergic reaction.
Pharmaceutical companies have invested billions of dollars over the decades in order to find the best allergy medication. One company in particular, GlaxoWellcome(NZ) Ltd., first released Beconase Nasal Spray as an aerosol spray in December 1974 on a prescription basis in New Zealand.
The Glaxo group is no stranger to the pharmaceutical and healthcare fields where the name is synonymous with many of the worlds leading products. With so much competition between pharmaceutical companies, the stakes are high and so are the capital investments. Pharmaceutical companies can only have a patent on their drugs for a limited time, thereafter other companies are allowed to create generic drugs with the same formula. Due to the fact that the initial investment in research is very high, the companies that release the generic formulas can sell their drugs at a much lower price as they did not invest anything in the research.
Pharmaceutical companies are often lambasted for selling their products at high prices, but this is necessary to cover the millions of dollars spent on research to develop their products.
Later on, an aqueous formulation with the same dose strength was released under the name Beconase Aqueous NasalSpray. This nasal spray was launched in August 1983, also under prescription, and was available in conjunction with Beconase Nasal Spray.
The aerosol formulation was discontinued in November 1995. Two years later, Beconase Aqueous Nasal Spray was rebranded as Beconase Hayfever. This was not due to a slump in sales. Between August 1983 and October 1998, over 1.5 million units of Beconase Aqueous Nasal Spray were sold under prescription in New Zealand alone. In the year following the relaunch, a further 100,000 units were sold on a restricted medicine basis.
As the worlds understanding of pharmaceuticals increased and more and more products of a similar nature were launched into the market, Glaxo realized that as long as the product was not of a harmful nature if taken in large doses, then it should be made more readily available to the public. With this in mind, Beconase became available as an OTC (over the counter) drug and sold over 3 million units in the UK alone between March 1994 and October 1998.
Beclomethasone dipropionate aqueous nasal spray, or more fondly and commonly known as Beconase, is currently available on a prescription basis in more than 70 countries and on a non-prescription basis in Germany, Switzerland, Finland, South Africa, New Zealand and the United Kingdom.
Beconase Aq Nasal Spray is a metered dose, manual pump spray unit which produces anti-inflammatory and vasoconstrictor effects. Clinical tests have shown that a significant symptomatic relief was present within 3 days. However, because humans are so diverse, relief for some members of the sample group only occurred after 3 weeks. Like all medication, the correct dosage prescribed by the medical healthcare professional should be strictly adhered to.